Harvard Bioscience/HBIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Harvard Bioscience

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Ticker

HBIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Scientific & Technical Instr.

CEO

James Green

Employees

391

Headquarters

Holliston, United States

HBIO Metrics

BasicAdvanced
$138M
Market cap
-
P/E ratio
-$0.20
EPS
1.27
Beta
-
Dividend rate
$138M
1.26992
$6.20
$3.09
100K
1.875
0.935
46.344
51.75
-0.40%
-6.26%
-12.20%
-7.60%
1.289
2
12.733
-6.76%
-305.23%
3.21%

What the Analysts think about HBIO

Analyst Ratings

Majority rating from 3 analysts.
Buy

HBIO Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-18.77% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$25M
-12.81%
Net income
-$4.6M
155.56%
Profit margin
-18.77%
193.28%

HBIO Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.28%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.04
$0.01
$0.04
$0.02
-
Expected
$0.06
$0.04
$0.05
$0.02
$0.05
Surprise
-36.84%
-75.00%
-20.00%
-14.28%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Harvard Bioscience stock?

Harvard Bioscience (HBIO) has a market cap of $138M as of June 17, 2024.

What is the P/E ratio for Harvard Bioscience stock?

The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of June 17, 2024.

Does Harvard Bioscience stock pay dividends?

No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next Harvard Bioscience dividend payment date?

Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for Harvard Bioscience?

Harvard Bioscience (HBIO) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Harvard Bioscience stock price target?

The target price for Harvard Bioscience (HBIO) stock is $6.92, which is NaN% below the current price of $. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Harvard Bioscience stock

Buy or sell Harvard Bioscience stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing